These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8889285)

  • 1. A study of dopaminergic sensitivity in Parkinson's disease: comparison in "de novo" and levodopa-treated patients.
    Llau ME; Durrieu G; Tran MA; Senard JM; Rascol O; Montastruc JL
    Clin Neuropharmacol; 1996 Oct; 19(5):420-7. PubMed ID: 8889285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyrotrophin and prolactin responses to thyrotrophin-releasing hormone in patients with Parkinson's disease.
    Martinez-Campos A; Giovannini P; Novelli A; Cocchi D; Caraceni T; Müller EE
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):344-51. PubMed ID: 6803485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-adrenergic sensitivity in Parkinson's disease: effect of levodopa treatment.
    Durrieu G; Rispail Y; Chatelut E; Berlan M; Rascol A; Montastruc JL; Montastruc P
    Clin Neuropharmacol; 1990 Dec; 13(6):492-9. PubMed ID: 2177376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
    Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of levodopa and bromocriptine on blood pressure and plasma catecholamines in parkinsonians.
    Durrieu G; Senard JM; Tran MA; Rascol A; Montastruc JL
    Clin Neuropharmacol; 1991 Feb; 14(1):84-90. PubMed ID: 2029695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A; Giovannini P; Parati E; Novelli A; Caraceni T; Müller EE
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Utility of the study of the vegetative nervous system in the differential diagnosis between Parkinson's disease and multiple system atrophy].
    Rouco I; Gómez JC; Lezcano E; Aniel-Quiroga MA; Velasco F; Barcena J; Pérez Bas M; Hurtado P; Cruz Lachén M; Zarranz JJ
    Neurologia; 2006 Apr; 21(3):119-23. PubMed ID: 16575624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208-243).
    Durrieu G; Senard JM; Rascol O; Tran MA; Lataste X; Rascol A; Montastruc JL
    Neurology; 1990 Apr; 40(4):707-9. PubMed ID: 2320249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson's disease.
    Ludwig J; Remien P; Guballa C; Binder A; Binder S; Schattschneider J; Herzog J; Volkmann J; Deuschl G; Wasner G; Baron R
    J Neurol Neurosurg Psychiatry; 2007 Jul; 78(7):742-5. PubMed ID: 17371906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.
    Jenner P; Falup-Pecurariu C; Leta V; Verin M; Auffret M; Bhidayasiri R; Weiss D; Borovečki F; Jost WH
    J Neural Transm (Vienna); 2023 Nov; 130(11):1337-1347. PubMed ID: 37210460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy.
    Friess E; Kuempfel T; Winkelmann J; Schmid D; Uhr M; Rupprecht R; Holsboer F; Trenkwalder C
    Arch Neurol; 2001 Feb; 58(2):241-6. PubMed ID: 11176962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration.
    Quadri R; Comino I; Scarzella L; Cacioli P; Zanone MM; Pipieri A; Bergamasco B; Chiandussi L
    Funct Neurol; 2000; 15(2):81-6. PubMed ID: 10916719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study versus placebo.
    Martignoni E; Horowski R; Liuzzi A; Costa A; Dallabonzana D; Cozzi R; Attanasio R; Rainer E; Nappi G
    Clin Neuropharmacol; 1996 Feb; 19(1):72-80. PubMed ID: 8867520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin response as an index of dopaminergic receptor function in Parkinson's disease. Correlation with clinical findings and therapeutic response.
    Agnoli A; Baldassarre M; Ruggieri S; Falaschi P; Urso RD; Rocco A
    J Neural Transm; 1981; 51(1-2):123-34. PubMed ID: 7264625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic influences on the P300 abnormality in Parkinson's disease.
    Sohn YH; Kim GW; Huh K; Kim JS
    J Neurol Sci; 1998 Jun; 158(1):83-7. PubMed ID: 9667783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease.
    Grandas F; Gancher ST; Rodriguez M; Lera G; Nutt JG; Obeso JA
    Clin Neuropharmacol; 1992 Feb; 15(1):13-8. PubMed ID: 1576595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypothalamic dysfunction in Parkinson's disease patients.
    Otake K; Oiso Y; Mitsuma T; Hirooka Y; Adachi K
    Acta Med Hung; 1994; 50(1-2):3-13. PubMed ID: 7638039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Giuffra M; Conant K; Davis TL; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):401-5. PubMed ID: 1865201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
    Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
    Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.